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Abstract 
Aims: Pulmonary congestion is an important finding in patients with heart failure (HF) that can 
be quantified by lung ultrasound (LUS). We conducted a systematic review to describe dynamic 
changes of LUS findings of pulmonary congestion (B-lines) in HF and to examine the prognostic 
utility of B-lines in HF. 
Methods and Results: We searched online databases for studies of patients with chronic or 
acute HF using LUS to assess dynamic changes or the prognostic value of pulmonary 
congestion. We included studies of adults, published in English, including ≥25 patients. Of 1327 
identified studies, 13 (n=25 to 290) met the inclusion criteria: 6 reported on dynamic changes in 
LUS findings (438 patients) and 7 on the prognostic value of B-lines in HF (953 patients). In 
acute HF, B-line number changed within as few as 3 hours of HF treatment. Among patients 
with acute HF, ≥15 B-lines on 28-zone LUS at discharge identified patients at a more than 5-fold 
risk for HF readmission or death. Similarly, in ambulatory patients with chronic HF ≥3 B-lines on 
5- or 8-zone LUS marked those at a nearly 4-fold risk of 6-month HF hospitalization or death. 
Conclusions: LUS findings change rapidly in response to HF therapy and may represent a 
useful, non-invasive method to track dynamic changes in pulmonary congestion. Furthermore, 
residual congestion at the time of discharge in acute HF or in ambulatory patients with chronic 
HF may identify those at high risk for adverse events. 
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Introduction 
Pulmonary congestion is a common finding in patients with heart failure (HF) and may itself 
contribute to worsening pulmonary vascular disease and biventricular HF.1 Although the 
pathophysiologic mechanisms are incompletely understood, the presence of pulmonary 
congestion in patients with HF may identify those at higher risk of HF hospitalizations and death, 
both in acute and chronic HF.1, 2 In addition, pulmonary edema can cause dyspnea which often 
limits patients’ activities, urges them to seek medical care and may lead to hospitalization. 
Pulmonary congestion is, therefore, an important therapeutic target in patients with HF. 
Traditionally, pulmonary congestion has been assessed by physical examination and chest 
radiography but more recently lung ultrasonography (LUS) has been identified as a sensitive 
and semi-quantitative tool in the assessment of pulmonary congestion in HF.3-5 B-lines are 
hyperechoic artifacts on LUS which appear as vertical lines that arise from the pleural surface 
and can be quantified in several zones of the chest.6 In the serial examination of patients with 
either chronic HF in the outpatient setting or with AHF requiring hospitalization, patient-reported 
symptom improvement and auscultation, in addition to other measures of treatment effect (e.g. 
urine output, weight loss) are currently used to guide therapy. In the absence of specific, 
quantitative measures both over- and under-treatment may occur. While over-treatment may 
result in orthostatic symptoms, including syncope or worsening renal function, under-treatment 
with associated residual congestion may lead to early readmissions.7, 8 In order to better 
delineate treatment targets for pulmonary congestion, the definition of both measurable 
treatment effects and prognostically relevant cut-off values are essential.9 
The goal of this systematic review was to describe the dynamic changes of LUS findings in 
patients with HF and to examine the prognostic utility of B-lines as well as potential cut-off 
values in patients with acute and chronic HF. Our hypotheses were that B-line number changes 
in response to therapy in patients with HF and that HF patients with a higher number of B-lines 
on LUS are at greater risk for adverse outcomes. 
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Methods 
We collected data from clinical studies of adult patients with HF to examine the dynamic 
changes and prognostic utility of B-lines on LUS. 
 
Literature search strategy 
We searched the electronic databases PubMed, EMBASE and Web of Science using relevant 
terms detailed in the Supplements. 
Eligibility criteria for inclusion in this systematic review were: Full text article available in English 
language, studies in humans, adults, sample size n≥25, study includes patients with HF, LUS 
used to assess dynamic changes and/or prognostic value of pulmonary congestion. We 
excluded studies that were available in abstract form only, review articles, those focused on 
non-HF populations, or those limited to diagnosing HF. We used the MOOSE checklist to 
describe the data collection and to identify potential biases of included studies (Table S1).10 
 
Data synthesis and statistical analyses 
We included all clinical studies regardless of the setting, chronicity of HF and ejection fraction. 
Eligible studies were divided into 4 groups: 1) Dynamic changes in B-line number in response to 
HF therapy, 2) Dynamic changes in B-line number in response to other interventions in patients 
with HF, 3) Prognostic value of B-lines in acute dyspnea and AHF, 4) Prognostic value of B-
lines in chronic HF. Reported variables were selected based on their relevance with respect to 
the study population, ultrasound methodology, intervention, study outcomes and potential 
confounders. 
For the prognostic assessment at the time of discharge from an AHF hospitalization (group 3) 
only those patients alive at the time of discharge and those with complete LUS data in group 4 
were included in the analyses. The HF hospitalization and all-cause mortality data for groups 3 
and 4 were reported as counts and percentages of the overall study cohort and both unadjusted 
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and adjusted hazard ratios were reported, if available. In random-effect meta-analyses we 
combined unadjusted hazard ratios for B-lines as categorical and continuous variables in 
studies limited to patients with HF, stratified by pre-discharge LUS findings (AHF) vs. LUS 
findings in ambulatory patients with chronic HF. Heterogeneity was assessed and interpreted 
using the I-squared statistic and forest plots. A P value <0.05 was considered statistically 
significant. All analyses were performed using STATA version 12.1 (Stata Corporation, College 
Station, Texas). 
 
Results 
Monitoring of dynamic changes in B-lines 
Patients, settings and interventions 
Results of the search and study selection are summarized in Figure 1. We identified 6 studies 
in Emergency Department (ED) or hospitalized patients with dyspnea or AHF (n=25 to n=152) 
(Table 1 One investigation assessed the impact of position change from sitting to supine in ED 
patients with prior HF. The remainder examined the impact of treatment during a hospitalization 
for AHF; however, the type of HF treatment was only specified in 2 studies, and HF treatment 
was not standardized in any of them. Patients with known conditions that may contribute to B-
line number independent of pulmonary edema due to HF, such as pulmonary fibrosis or end-
stage renal disease requiring dialysis, were excluded from some but not all publications (Table 
S2).6  
 
Ultrasound equipment, imaging protocol and analysis 
Ultrasound equipment and imagine protocols are summarized in Table 1. Investigators 
examined between 4 and 28 chest zones. Figure 2 illustrates two types of imaging protocols 
and LUS image examples with and without B-lines.6, 11, 12 Several different quantification 
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methods were employed: Broadly, these can be categorized into two groups, a count based 
method, summing B-lines across several pre-specified chest zones and a score based method, 
in which a chest zones is considered “positive” if a certain number of B-lines is seen. Three 
studies performed concomitant echocardiography at the time of LUS assessment and one also 
examined the presence of pleural effusions. B-line quantification was performed blinded to 
some or all clinical findings in four studies and blinding was not specified in the remaining ones 
(Table S2).  
 
Time interval and change in B-line number 
Time intervals ranged from minutes to several days during the hospitalization and were not 
specified in one study. All publications reported a change in B-line number or score following 
their intervention. Two AHF studies, which used the same 28-zone quantification method, 
reported a mean change of 22 B-lines (53.4 (±17.2) to 31.7 (±13.5); P<0.01) after 24 hours of 
treatment and 28 B-lines (48 (±48) to 20 (±23); P<0.0001) between admission and discharge. 
Two other AHF studies examined B-lines in 11 zones and found a significant reduction in 
“positive” LUS zones (based on a score) in 3 hours of HF therapy, and between admission and 
discharge. Only one of the reviewed publications reported temporal blinding of the ultrasound 
readers (Table S2).13 
 
Prognostic value of lung ultrasound in HF 
Patients and settings 
We identified 7 publications which reported on the prognostic utility of LUS: Two in hospitalized 
patients with acute dyspnea (n=66 and n=290), 3 in patients hospitalized for AHF (n=60 to 
n=149) and 2 in ambulatory, chronic HF populations (n=104 and n=195) (Table 2).  The majority 
of studies included both patients with HF with reduced ejection fraction (HFrEF) and HF with 
preserved EF (HFpEF) but none presented results stratified by EF. Four studies excluded 
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patients with conditions that may have contributed to an increased number of B-lines 
independent of pulmonary edema due to HF (Table S3). 
 
Ultrasound equipment, imaging protocol and analysis 
Ultrasound equipment and imaging protocols are summarized in Table 2. In contrast to the 
acute dyspnea and AHF studies, investigators used pocket ultrasound devices to acquire LUS 
images in 2 chronic HF publications. Imaging protocols were similar to those described for the 
assessment of dynamic changes in B-line number, ranging from 5 to 28 zones and 
quantification methods included count and score measures. One chronic HF study also included 
the assessment of posterior lung zones.14 B-line quantification was performed blinded to clinical 
findings in 4 investigations but whether the image analysis was performed in real-time or off-line 
was only specified in 2 (Table S3). All acute dyspnea and AHF studies reported performance of 
concomitant echocardiography and 2 also reported assessment of pleural effusions. Neither of 
the chronic HF publications reported concomitant assessment of echocardiography but one 
included pleural effusions. 
 
Outcomes and meta-analysis 
One acute dyspnea  publication reported ICU mortality rates, all other acute dyspnea, acute and 
chronic HF studies reported composite outcomes including HF hospitalizations or worsening HF 
and either all-cause or CV death. Follow-up time ranged from 3 months to a median of 18 
months. Events were verified by a variety of methods (Tables 2 and S3). The mean/median age 
in the acute dyspnea, acute and chronic HF studies ranged from 50 to 81 years and median EF 
from 37 to 48%. HF hospitalization rates ranged between 6.9 and 25% and all-cause mortality 
rates from 4 to 16.7% over the follow-up period. Unadjusted and adjusted hazard ratios by B-
line method and cut-off values are reported in Table 3.  
9 
 
Meta-analyses were performed for those acute and chronic HF studies reporting composite 
outcomes of HF hospitalizations (or worsening HF) and death. The pooled hazard ratio for 3 to 5 
month HF readmission or death in 308 patients being discharged from the hospital after an AHF 
episode was 5.56 (95% CI 2.24, 13.80; P<0.001) suggesting that ≥15 B-lines on 28-zone LUS 
identifies patients at risk for subsequent adverse events (Figure 2). This pooled hazard ratio 
should be interpreted in the context of the heterogeneity analysis comparing the occurrence of 
these events across the 3 studies (I-squared 40.3%, P=0.187). For 289 patients with chronic HF 
the pooled hazard ratio for 6-month HF hospitalization or death was 3.41 (95% CI 2.02, 5.75; 
P<0.001) indicating that ≥3 B-lines in 5-8 chest zones identifies patients at risk for these 
adverse events (Figure 2).  
 
Incremental prognostic value of lung ultrasound findings 
The incremental value of LUS beyond traditional risk markers was assessed by two studies: In 
one AHF study of 60 patients the addition of ≥30 B-lines (28 zones) at the time of discharge 
provided incremental prognostic information with respect to 3-month HF readmission or all-
cause death beyond NYHA class and baseline log BNP (IDI 15%, P=0.02; continuous NRI 65%, 
P=0.03).15 In a subset of 51 patients, the addition of log BNP did not provide incremental 
prognostic information beyond NYHA, while ≥30 B-lines at the time of discharge may (IDI 17%, 
–1% to 43%, P=0.09; continuous NRI=66%, –30% to 84%, P=0.07). Similarly, in one chronic HF 
study of 185 ambulatory patients (NYHA II-IV) ≥3 B-lines (8 zones) the incremental prognostic 
value of LUS when compared with auscultation as assessed by the IDI was 6.4% (95% CI 1.0, 
14.4) and 0.194 by the AUC delta (95% CI 0.147, 0.315; P=0.001) for 6-month HF 
hospitalizations or all-cause death.16 The incremental prognostic value of LUS when compared 
with a congestion score by the IDI was 6.6% (95% CI: 1.9, 15.1) and 0.136 by the AUC delta 
(95% CI 0.082, 0.228; P=0.002) for the primary outcome. 
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Discussion 
This systematic review of clinical studies in adult patients with HF evaluated by LUS had two 
principal findings: first, in patients hospitalized for AHF, B-line number on LUS changes within 
as few as 3 hours of HF treatment. The number of B-lines may also change within minutes 
following position change from sitting to supine. Second, among patients who were hospitalized 
for AHF, ≥15 B-lines on discharge 28-zone LUS identify patients at a more than 5-fold risk for 
HF readmission or death. Similarly, in ambulatory patients with chronic HF, ≥3 B-lines on 5- or 
8-zone LUS marked those at a nearly 4-fold risk of 6-month HF hospitalization or death. These 
data should be considered hypothesis generating given the heterogeneity of the reviewed AHF 
studies and overall small sample size.   
 
Can lung ultrasound be used to monitor pulmonary congestion? 
The quantitative assessment of adequate peripheral and pulmonary decongestion in HF 
continues to represent a challenge for both clinicians and clinical trialists.7, 17 Thus, novel, 
quantitative measures are essential in order to evaluate the effect of current and new therapies, 
to determine when therapy may need to be adjusted and when patients can be safely 
discharged from the hospital.  Although based on a small number of studies, our findings from 
this systematic review suggest that LUS may enable tracking of changes in pulmonary 
congestion with treatment. The varied number of imaging protocols and quantification methods, 
as well as a lack of standardized therapy, make the comparison of these trials difficult and as 
such our results must be interpreted with caution. Moreover, the lack of blinding of ultrasound 
readers, e.g. to clinical findings, may introduce bias. Based on the limited available data, 
scanning as few as 11 lung zones could provide sufficient information over the course of 3 
hours to a mean of 4.2 days to identify a change in the number of positive zones in patients 
hospitalized for AHF. These findings will need to be confirmed in larger, well designed studies. 
At least based on the findings of one AHF study, patient positioning should be kept constant for 
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serial assessments in order to avoid measurement of dynamic changes due to position change 
alone. This finding is in line with those from a study in which lung impedance appeared to be 
sensitive to changes in body position.18 In a small trial of 25 AHF patients with HFrEF the mean 
B-line number was slightly higher at baseline (mean 53.4 ±17.2) than in a mixed HFrEF and 
HFpEF cohort of 100 AHF patients (mean 48 ± 48) employing the same 28-zone scan protocol. 
Despite different time intervals both studies reported significant changes in B-line number with 
HF therapy.  Whether B-lines are similarly prevalent and change at a similar rate in patients with 
HFrEF vs. HFpEF warrants further investigation.  
 
Does lung ultrasound provide prognostic information in HF? 
All-cause mortality rates in recent AHF trials including both patients with HFrEF and HFpEF 
range from 12% for 90 days to 11-21% for 180 days of follow-up.11 All-cause mortality rates 
were lower (4 and 7.4%) in two of the AHF trials we reviewed despite similar follow-up periods 
and age range as in recent AHF trials. However, these acute HF trials enrolled patients with 
lower mean EF than the ones included in our review which may explain the associated higher 
mortality rates in these trials. Reported rates for HF readmissions varied substantially between 
the reviewed studies, and, with the exception of one,15 were lower than those in recent AHF 
trials (6% for 30 days), AHF registries or national databases (24-31% for 30-90 days).19-21 The 
lower event rates, especially for HF readmissions, in the publication by Gargani et al., may 
explain the heterogeneous results of the meta-analysis for the reviewed AHF trials. The 6-month 
event rates of the 2 LUS studies in patients with chronic HF were relatively high compared with 
recent chronic HF trials in patients with HFrEF or HFpEF.22 Nevertheless, our data suggest that 
a high number of B-lines identifies patients at greater risk of subsequent HF hospitalizations and 
mortality in studies of both acute and chronic HF. Findings of studies reporting the evaluation of 
fewer chest zones (5 to 8) seem to provide similar prognostic information as those with a higher 
number of zones evaluated (e.g. 28 zones). The potential utility of protocols evaluating fewer 
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chest zones is an important area of research and requires further investigation. By reducing the 
number of zones scanned, and therefore reducing the exam time, the test will potentially 
become more widely used. Standardized image acquisition and analysis, blinded to clinical 
findings will be important to allow comparison of study results across trials and develop 
meaningful cut-off values.  
 
Current gaps in knowledge 
Based on this systematic review there are a number of gaps in the current literature. It is unclear 
what an important or sufficient change in the B-line number in response to standardized 
treatment for AHF is and whether adequately treated AHF patients at the time of discharge 
should achieve a similarly low B-line number as ambulatory patients with chronic HF. 
Standardized reporting of LUS measures (e.g. number of zones), both continuous and 
categorical would be an important feature of future HF trials reporting LUS findings in order to 
facilitate comparison of findings across trials. There is also a lack of data describing the 
prevalence of LUS findings in different HF phenotypes such as HFrEF vs. HFpEF both in acute 
and in chronic HF, as well as the response to therapy by HF group and prognostically important 
cut-off values. In addition, the incremental value of LUS in the monitoring and prognosis of 
patients with HF beyond other markers of congestion and risk in this population warrants further 
investigation.  
 
Limitations 
Our systematic review is limited by the small number of studies and small sample size reporting 
on dynamic changes and prognostic value of LUS findings in HF. The small sample size also 
allowed for only limited assessment of the incremental value of LUS beyond traditional clinical 
and biochemical risk markers such as congestion score, NYHA class or natriuretic peptides.  In 
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addition, the lack of standardization of the number of evaluated chest zones and B-line 
quantification methods make it difficult to compare findings across studies and perform meta-
analyses. Nevertheless, we believe that this systematic review provides hypothesis generating 
data that can inform future HF trials. 
 
Conclusions 
Among patients hospitalized for AHF, B-line number on LUS decreases with HF treatment. A 
large number of B-lines in both patients with acute and chronic HF identify those at high risk for 
HF hospitalization or death. These data suggest that LUS may represent a useful, non-invasive 
method to track dynamic changes in pulmonary congestion in response to treatment and that 
residual congestion at the time of discharge or in ambulatory patients with chronic HF may 
identify those at high risk for decompensation. 
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Table 1. Overview of lung ultrasound technique in acute and chronic HF: Dynamic changes in B-lines 
 
Author  
(year) 
Cohort n Ultrasound 
system & 
transducer 
Number 
of zones 
Method B-line 
quantification 
 
Pleural 
effusions/ 
echo 
Intervention Time 
interval 
Change in  
B-lines 
Monitoring: Dynamic changes in B-lines with HF therapy 
Volpicelli 
(2008)23 
Dyspnea, ED 
then 
hospitalized, 
“established 
diagnosis of 
AHF” 
70 High-end, 
convex 
11 Score If >2 B-lines/zone 
= positive zone 
Score = number 
of positive zones 
No HF treatment 4.2 (±1.7) 
days  
Pre: Median 8 
positive zones 
(range: 3-9)  
Post: 0 positive 
zones (range: 0-
7) (P<0.05) 
Change: Median 
8 positive zones 
Vitturi 
(2011)24 
Dyspnea, 
hospitalized 
medicine 
patients; 45% 
treated for HF 
152 High-end, 
convex 
NR Count >8 B-lines No 45% treated 
for HF  
48 hours Decrease in B- 
lines at 48 h 
greater (P< 
0.005) among 
patients treated 
for HF 
Gargani 
(2015)25 
Hospitalized for 
AHF (HFrEF & 
HFpEF) 
100 High-end, 
phased 
28 Score & 
Count 
Score: 
Mild: 6-15 B-lines 
Moderate: 16-30 
Severe: >30 B-
lines; 
Count: 
Sum of B-lines in 
all zones 
Echo & 
pleural 
effusions 
HF treatment Admission 
and 
discharge 
(time 
period NR) 
Pre: Mean 48 
(±48) B-lines  
Post: 20 (±23) (P 
<0.0001); 
Change: Mean 
28 B-lines 
Facchini 
(2016)26 
ED, then 
hospitalized 
(HFrEF)  
25 High-end, 
phased 
28 Count Sum of B-lines in 
28 zones vs. right 
hemithorax only;  
if sum <5 B-lines, 
then = 0 B-lines 
Echo Intravenous 
furosemide 
(125-250 mg 
total), +/- 
other 
diuretics 
24 hours Pre: Mean 53.4 
(±17.2) B-lines 
Post: 31.7 
(±13.5)  (P<0.01); 
Change: Mean 
21.7 B-lines 
20 
 
Cortellaro 
(2016)27 
Clinical and 
imaging 
findings of 
pulmonary 
congestion; 
ED, then 
hospitalized for 
AHF (HFrEF & 
HFpEF) 
41 High-end, 
convex 
11 Score 0 points: <3 B-
lines in a zone, 
1 point: ≥3 B-
lines in ≥1 zone, 
2 points: Multiple/ 
confluent B-lines 
Echo  
(not at 
time of 
LUS) 
Intravenous 
furosemide, 
nitroglycerin, 
morphine 
and/or non-
invasive 
ventilation 
3 and 24 
hours 
Pre: Mean score 
1.59 (± 0.40) 
Post 3h:  
0.73 (± 0.44) 
Post 24h: 
0.38 (± 0.44) 
Monitoring: Dynamic changes in B-lines in HF with other interventions 
Frasure 
(2014)13 
ED, prior HF 
(HFrEF & 
HFpEF) 
50 High-end, 
phased 
Both 4 & 
8 
Score 0–2 B-lines: 0 
points  
3–7 B-lines: 1 
point  
>7 B-lines: 2 
points 
No Position 
change from 
sitting to 
supine 
2 minutes 
after 
position 
change  
Sitting: Median 
score 5 (IQR 1–
8) 
Supine: 6 (IQR 
2–10); 
Change: Median 
1 score 
 
Legend: 
ED: Emergency Department, AHF: Acute heart failure, NR: Not reported, HFrEF: Heart failure with reduced ejection fraction, HFpEF: 
HF with preserved EF, NYHA: New York Heart Association, IQR: Interquartile range 
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Table 2. Prognostic value of lung ultrasound in HF (I) 
 
Author  
(year) 
Cohort n Ultrasound 
system & 
transducer 
Number 
of zones 
Method B-line 
quantification  
Pleural 
effusions/ 
echo 
Criteria 
standard 
(outcome) 
Outcome 
Acute dyspnea 
Frassi 
(2007)28 
Hospitalized 
patients with 
dyspnea or 
chest pain, 49% 
with h/o chronic 
HF 
290 High-end, 
phased 
28 Score Mild: 5-14 B-lines 
Moderate: 15-29 
Severe: ≥30 B-
lines 
Echo Medical 
records, 
contact with 
family or 
physician 
signing death 
certificate 
Composite: 
All-cause 
death, CV 
death, 
worsening HF 
(median 
follow-up 16 
months) 
Wang 
(2014)29 
ICU patients, 
acute dyspnea, 
paO2<300 
mmHg & pulm. 
edema on CXR 
66 High-end, 
transducer 
NR 
NR NR Multiple bilateral B-
lines 
Echo NR ICU mortality 
Acute heart failure 
Gargani 
(2015)25 
Hospitalized for 
AHF (HFrEF & 
HFpEF), pre-
discharge 
99 High-end, 
phased 
28 Score & 
Count 
Score: 
Mild: 6-15 B-lines 
Moderate: 16-30 
Severe: >30 B-
lines; 
Count: 
Sum of B-lines in 
all zones 
Echo & 
pleural 
effusions 
At least 1 of 4 
sources: 
Medical 
records, 
patient’s 
physician, 
patient 
Composite: 
HF 
hospitalization 
or death 
(mean follow-
up 159 days) 
Coiro 
(2015)15 
Hospitalized for 
AHF (HFrEF & 
HFpEF), pre-
discharge  
60 High-end, 
phased 
Both 8 & 
28 
Score & 
Count 
Score:  
≥3 B-lines per zone 
= positive zone; 
Count: Sum of B-
lines in all zones 
Echo Medical 
records & 
telephone 
contact 
Composite: 
3 month HF 
hospitalization 
or death 
Cogliati 
(2016)30 
Hospitalized for 
AHF (HFrEF & 
HFpEF), pre-
discharge 
149 High-end, 
curved 
Both 8 & 
28 
Score (8 
zones); 
Count 
(28 
zones) 
Score:  
≥3 B-lines per zone 
= positive zone; 
Count: Sum of B-
lines in all zones 
Echo & 
pleural 
effusions 
Medical 
records, 
contact with 
physician or 
caregivers; 
review by 2 
physicians 
Composite: 
100 day HF 
hospitalization 
or all-cause 
death 
22 
 
 
Chronic heart failure 
Gustafsson 
(2015)14 
Chronic HF 
(NYHA I-III),  
HFrEF & HFpEF 
104 Pocket, 
phased 
5 Count & 
Score 
Score:  
>3 B-lines in one 
zone; 
Count: 
Sum of B-lines in 
all zones  
Pleural 
effusion 
Medical 
records 
Composite: 
6 month HF 
hospitalization 
or all-cause 
mortality 
Platz 
(2016)16 
Chronic HF 
(NYHA II-IV), 
HFrEF & HFpEF 
185 Pocket, 
phased 
8 Count Sum of B-lines in 
all zones 
No Medical 
records, 
national death 
database, 
physicians & 
patients; 
adjudicated  
by 3 
cardiologists 
Composite:  
6 month HF 
hospitalization 
or all-cause 
mortality  
 
Legend: 
High-end: Conventional ultrasound system, ICU: Intensive care unit, NR: Not reported, AHF: Acute heart failure, HFrEF: Heart failure 
with reduced ejection fraction, HFpEF: HF with preserved EF, NYHA: New York Heart Association, Pocket: Pocket ultrasound device  
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Table 3. Prognostic value of lung ultrasound in HF (II) 
 
Author  
(year) 
n Mean age 
(years) 
Mean EF 
(%) 
Median NT-
proBNP 
(pg/ml) 
HF re-
admissions 
n (%)* 
All-cause 
deaths  
n (%) 
Total 
events  
n (%) 
Unadjusted 
HR (95% CI) 
Adjusted HR 
(95% CI) 
Covariates B-line  
cut off 
 
Acute dyspnea 
Frassi 
(2007)28 
290 68 (±13) 45 (±14) - 20 
(6.9)  
39 
(13.5) 
59  
(20.3) 
2.35  
(1.36-4.00) 
1.9  
(1.1-3.4) 
Diabetes, 
NYHA 
Continuous 
(28 zones) 
Wang 
(2014)29 
66 50 (±10) - Mean 4125 
(±3843) 
N/A 4 
(6.1) 
4  
(6.1) 
- - - N/A 
Acute heart failure 
Gargani 
(2015)25 
99 70 (±11) 37 (±14) Mean 5291  
(±5877) 
14  
(14.1) 
4 
(4.0) 
18 
(18.2) 
1.03  
(1.01–1.04) 
NS NYHA, 
hemoglobin 
<10 m/dl,  
NT-proBNP 
>1635 ng/l at 
discharge,  
>50 B-lines at 
admission 
Continuous 
(28 zones) 
24.12  
(3.15–184.55) 
11.74  
(1.30–106.16) 
>15 B-lines 
(28 zones) 
Coiro 
(2015)15 
60 72 (±10) Median 
38  
(IQR 27–
52) 
BNP 
575  
(229–1147) 
15 
(25.0) 
10 
(16.7) 
18  
(30.0) 
1.03  
(1.02–1.05) 
NS NYHA ≥III,  
IVC diameter 
 
Continuous 
(28 zones) 
5.8  
(2.1–16.3) 
NS ≥15 B-lines 
(28 zones) 
9.94  
(3.51–28.20) 
5.66  
(1.74–8.39) 
≥30 B-lines 
(28 zones) 
12.7 
(4.8-33.69) 
4.2 
(0.8-21.1) 
≥2 positive 
zones  
(of 8 zones) 
7.51  
(2.88–19.57) 
3.30  
(1.00–10.91) 
≥1 positive 
zone  
(of 8 zones) 
Cogliati 
(2016)30 
149 Median 81  
(IQR 76–
85) 
48 (±17) 2407  
(1032–
5273)† 
23 
(15.4) 
11 
(7.4) 
34  
(22.8) 
1.005  
(1.002 -1.008) 
NS NT-proBNP 
category† 
 
Continuous  
(28 zones) 
3.10  
(1.20- 8.02) 
NS >15 B-lines 
(28 zones) 
2.85  
(1.36- 5.96) 
NS >30 B-lines 
(28 zones) 
3.62  
(1.76- 7.43) 
NS ≥2 positive 
zones  
(of 8 zones) 
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Chronic heart failure 
Gustafsson 
(2015)14 
104 72 (±13) - 1820  
(870-3800) 
18 
(17.3) 
14 
(13.5) 
24 
(23.1) 
3.0  
(1.4-6.7) 
3.5  
(1.5-7.9) 
Age >72 yrs, 
EF<40% 
>3 B-lines 
(5 zones) 
2.9  
(1.3-6.6) 
Age >72 yrs, 
EF<40%, log 
NT-proBNP 
Platz 
(2016)16 
185 66 (±15) 37 (±16) 2519   
(1070- 
5080)‡ 
44 
(23.8) 
13 
(7.0) 
50 
(27.0) 
3.78  
(1.88-7.63) 
4.08  
(1.95-8.54) 
Age, sex, 
NYHA class 
III or IV, 
congestion 
score 
≥3 B-lines 
(8 zones) 
 
Legend: 
* Or worsening heart failure 
† NT-proBNP in a subset of n=99 patients 
‡ NT-proBNP in a subset of n=97 patients within 7 days of clinic visit 
 
EF: Ejection fraction, (NT-pro)BNP: (NT-pro) Brain natriuretic peptide, HR: hazard ratio, NYHA: New York Heart Association, IVC: 
Inferior vena cava, N/A: Not applicable, NS: Not significant 
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Figure 1. Literature search results 
 
 
Legend: 
HF: Heart failure, LUS: Lung ultrasound; AHF: Acute HF 
 
 
 
Figure 2. Examples of lung ultrasound scanning protocols and images 
 
 
Legend: 
Panel A: 8-zone method; in chronic HF ≥3 B-lines identified patients at nearly 4-fold risk of 6-month HF hospitalization or death. 
Panel B: 28-zone method; in patients with AHF ≥15 B-lines at the time of hospital discharge identified patients at more than 5-fold 
risk for HF readmissions or death. 
Panel C: Lung ultrasound image without B-lines. 
Panel D: Lung ultrasound image with several B-lines.  
 
 
 
Figure 3. Unadjusted HR for HF hospitalization or death with B-lines at hospital discharge (AHF) and in chronic HF (n=597) 
 
 
Legend:  
Cut-off >15 B-lines (28 zones) for AHF pre-discharge from the hospital, and ≥3 B-lines (5-8 zones) for chronic HF (ambulatory 
patients); x-axis is on a logarithmic scale 
 
1327 unduplicated search 
results 
 
13 studies related to  
dynamic changes in LUS in HF or 
prognostic value of LUS in HF 
 
Excluded:  
• 918 studies unrelated to HF or LUS in 
adult humans, not available in English, or 
not meeting cut-off of n 25 patients*  
• 114 Review Articles, Editorials, 
Commentaries  
• 125 Case Reports 
• 110 Meeting Abstracts 
Sub-division of 13 studies into 4 groups:  
1) Dynamic changes in B-line number in response to HF therapy (n=5) 
2) Dynamic changes in B-line number in response to other 
interventions in patients with HF (n=1) 
3) Prognostic value of B-lines in  acute dyspnea (n=2) and AHF (n=3) 
4) Prognostic value of B-lines in chronic HF (n=2)  
 60 studies related to LUS in HF with 
n 25 patients 
Excluded: 
47 studies of LUS in HF unrelated to topics 
addressed in this review (e.g. HF diagnosis, 
hemodynamics, correlation with BNP, etc.) 
